Biogen (BIIB) - Stock Price & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US09062X1037

Multiple Sclerosis, Alzheimer's, Biosimilars, Cancer, Psoriasis

Biogen Inc. is a pioneering biotechnology company that discovers, develops, manufactures, and delivers innovative therapies to treat a wide range of neurological and neurodegenerative diseases. With a strong presence in the United States, Europe, Germany, Asia, and internationally, the company is dedicated to improving the lives of patients worldwide.

The company's portfolio of treatments includes TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS), as well as SPINRAZA for spinal muscular atrophy. Additionally, Biogen offers ADUHELM, a groundbreaking treatment for Alzheimer's disease, and FUMADERM for plaque psoriasis. The company also provides a range of biosimilars, including BENEPALI, IMRALDI, FLIXABI, and BYOOVIZ, which are designed to increase access to affordable and effective treatments.

Biogen's oncology portfolio includes RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS, LUNSUMIO, and glofitamab, which are used to treat various types of blood cancer, including non-Hodgkin's lymphoma and chronic lymphocytic leukemia. These therapies have revolutionized the treatment of these diseases, offering new hope to patients and their families.

The company is also committed to advancing the development of new treatments for neurological and neurodegenerative diseases. Biogen's research and development pipeline includes promising new therapies for MS, Alzheimer's disease, Parkinson's disease, and other conditions. Through collaborations with other companies and organizations, Biogen is pushing the boundaries of medical innovation, exploring new ways to prevent, diagnose, and treat some of the world's most debilitating diseases.

Founded in 1978, Biogen is headquartered in Cambridge, Massachusetts, and has established itself as a leader in the biotechnology industry. With a strong commitment to patients, innovation, and collaboration, Biogen is poised to continue making a meaningful impact on the lives of people around the world. For more information, please visit

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for Biogen (BIIB) - Stock Price & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for Biogen (BIIB) - Stock Price & Dividends

BIIB Stock Overview

Market Cap in USD 32,238m
Sector Healthcare
Industry Drug Manufacturers - General
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 1991-09-16

BIIB Stock Ratings

Growth 5y -1.91
Fundamental -1.67
Dividend -
Rel. Performance vs Sector -3.61
Analysts 4.21/5
Fair Price Momentum 202.87 USD
Fair Price DCF 241.79 USD

BIIB Dividends

Yield 12m 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Payout Consistency 0.0%

BIIB Growth Ratios

Growth 12m -24.53%
Growth Correlation 12m -76%
Growth Correlation 3m -16%
CAGR 5y 0.21%
CAGR/Mean DD 5y 0.01
Sharpe Ratio 12m -1.25
Alpha vs SP500 12m -47.80
Beta vs SP500 5y weekly 0.78
ValueRay RSI 93.49
Volatility GJR Garch 1y 70.15%
Price / SMA 50 8.6%
Price / SMA 200 -3.24%
Current Volume 705.6k
Average Volume 20d 1289.4k

External Links for BIIB Stock

Wall Street JournalBenzingaYahoo Finance
Fund Manager Positions
What is the price of BIIB stocks?
As of May 21, 2024, the stock is trading at USD 231.58 with a total of 705,561 shares traded.
Over the past week, the price has changed by +2.77%, over one month by +19.14%, over three months by +5.64% and over the past year by -24.93%.
What are the forecast for BIIB stock price target?
According to ValueRays Forecast Model, BIIB Biogen will be worth about 222.7 in May 2025. The stock is currently trading at 231.58. This means that the stock has a potential downside of -3.82%.
Issuer Forecast Upside
Wallstreet Target Price 285.1 23.1
Analysts Target Price 330.8 42.8
ValueRay Target Price 222.7 -3.82